

A *PSEUDOMONAS FLUORESCENS* BASED PLATFORM FOR ROBUST VACCINE MANUFACTURING

Russell Coleman, Pfenex Inc.
rcoleman@pfenex.com

Key Words: Pseudomonas, high-throughput screening, vaccines

Pfenex Expression Technology™ has been developed specifically as a protein production platform to enable rapid development of high quality protein therapeutics including novel vaccines and biosimilars. Pfenex represents a new paradigm of microbial strain development that overcomes today's slow, iterative, error-prone process through use of a robotically-enabled, high-throughput parallel strain screening technology, delivering unprecedented speed and success in identifying protein production strains capable of producing large amounts of soluble, active product. Capitalizing on the efficiencies of our platform technology, we are able to effectively develop lower cost, higher quality vaccines including a novel rPA based anthrax vaccine.